8-K: Heart Test Laboratories Faces Delisting, Implements 1-for-100 Reverse Stock Split

Heart Test Laboratories, Inc. is facing potential delisting from the Nasdaq Capital Market due to low stock price and has implemented a 1-for-100 reverse stock split to regain compliance.

Summary

• Heart Test Laboratories, Inc. received a delisting notice from Nasdaq because its stock price closed at $0.10 or less for ten consecutive trading days.
• The company has been granted an extension until July 29, 2024, to regain compliance with the minimum bid price requirement of $1 per share.
• To address this, the company has implemented a 1-for-100 reverse stock split of its common stock and warrants.
• This means every 100 pre-split shares will become 1 post-split share, and the warrant exercise price will increase to $425.00.
• The company intends to appeal the delisting decision and has requested a hearing with Nasdaq.
• A quorum for shareholder meetings has been reduced to one-third of the shares entitled to vote.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the need for a significant reverse stock split, indicating serious financial challenges. While the company is taking action, the outcome is uncertain.

Positives

• The company is taking action to regain compliance with Nasdaq listing requirements by implementing a reverse stock split.
• The company has requested a hearing with Nasdaq to appeal the delisting decision, which will stay the delisting process pending the panel's decision.
• The reverse stock split will not affect any stockholder's ownership percentage, except for rounding up fractional shares.

Negatives

• The company received a delisting notice from Nasdaq due to its low stock price.
• The company's stock price has been below $0.10 for at least ten consecutive trading days.
• There is no guarantee that the company will regain compliance with Nasdaq listing rules despite the reverse stock split.

Risks

• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement and the low priced stocks rule.
• The company faces the risk of being delisted from the Nasdaq Capital Market if it fails to regain compliance.
• The reverse stock split may not be sufficient to increase the stock price to the required level.
• The company's ability to raise capital may be impacted by the delisting risk.

Future Outlook

The company intends to appeal the delisting decision and implement a reverse stock split to regain compliance with Nasdaq listing standards, but there is no guarantee of success.

Management Comments

• The company intends to appeal the Staff Determination under the Low Priced Stock Rule and will file a hearing request with Nasdaq by May 16, 2024.
• The company expects to effect the Reverse Stock Split in the market as soon as possible after confirmation from Nasdaq.

Industry Context

This announcement reflects the challenges faced by companies with low stock prices in maintaining their listing on major exchanges like Nasdaq. Reverse stock splits are a common strategy to address this issue, but they do not guarantee long-term compliance.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies facing delisting from exchanges like Nasdaq, similar to actions taken by other companies in the biotech and small-cap sectors.
• The 1-for-100 reverse split is a significant ratio, indicating the severity of the stock price decline, which is more aggressive than some other companies that have used 1-for-10 or 1-for-20 splits.
• Companies like Cassava Sciences and Ocugen have also faced similar delisting threats and have implemented reverse stock splits to regain compliance, although the specific ratios and circumstances may vary.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split, but their ownership percentage will remain the same, except for rounding up fractional shares.
• The company's employees may be concerned about the company's financial stability and the potential impact of delisting.
• The company's creditors may be concerned about the company's ability to repay its debts if it is delisted.

Next Steps

• The company will file a hearing request with Nasdaq by May 16, 2024.
• The company will implement the 1-for-100 reverse stock split as soon as possible after confirmation from Nasdaq.
• The company will announce the date on which the stock will trade on a split-adjusted basis.

Key Dates

Keywords

reverse stock split, delisting, Nasdaq, minimum bid price, compliance, warrants, quorum, stock price